Plegee Sunday, 06/28/20 06:02:35 PM Re: None Post # of 1139 It appears that the Company does not have the shareholder votes to re-elect the Board of Directors nor approve the ridiculous compensation management is getting. We will know tomorrow (if not postponed). I hope all proposals fail. Cooper is not CEO material, not even senior manager level of any kind. Never invest in a biotech with an MD at the helm, never; no matter how promising. So many clinical deadlines have passed, so many promises broken, no urgency to get things done; no fiduciary sense of any kind, no shareholder accountability. All this without a modicum of explanation of any kind to the shareholders. The ridiculous secondary of four months ago was the last straw, literally conceding to shorts by allowing them to `invest' and cover. . . . the same people who have tried to bankrupt this company for the last five years. The company may take a $$ hit on this but will ultimately be placed in more competent hands; we can not get any worse decision making than present. We have no idea after five years of what, if any, of this `ground breaking' technology clinically works. Clearly there are issues with the NCI. Programs invested in five years ago just drop off the company radar with no comment by management. Worst company I have ever encountered. Millions of bonuses and compensation to Cooper over the years and he has not once bought a single share in this company; just the recipient of endless gifts. Complete disgrace. Don't want him as CMO either. Carl June to the rescue please.